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Background—More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization
factors that might explain this association.
Methods and Results—A multivariate logistic regression model was used to identify baseline predictors of stroke in 4038
patients with diabetes mellitus, chronic kidney disease, and anemia randomized to receive darbepoetin alfa or placebo.
To determine whether postrandomization blood pressure, hemoglobin level, platelet count, or treatment dose were
responsible for the increased risk related to darbepoetin alfa, we performed a nested case-control analysis (1:10
matching) identifying nonstroke controls with propensity matching. The risk of stroke was doubled with darbepoetin
alfa. Overall, 154 patients had a stroke, 101/2012 (5.0%) in the darbepoetin alfa arm and 53/2026 (2.6%) in the placebo
arm (hazard ratio 1.9; 95% confidence interval, 1.4–2.7). Independent predictors of stroke included assignment to
darbepoetin alfa (odds ratio 2.1; 95% confidence interval, 1.5–2.9), history of stroke (odds ratio 2.0; 95% confidence
interval, 1.4–2.9), more proteinuria, and known cardiovascular disease. In patients assigned to darbepoetin alfa,
postrandomization systolic and diastolic blood pressure, hemoglobin level, platelet count, and darbepoetin alfa dose did
not differ between those with and without stroke. Additional sensitivity analyses using maximal values, latest values,
or changes over varying periods of exposure yielded similar results.
Conclusions—The 2-fold increase in stroke with darbepoetin alfa in TREAT could not be attributed to any baseline
characteristic or to postrandomization blood pressure, hemoglobin, platelet count, or dose of treatment. These readily
identifiable factors could not be used to mitigate the risk of darbepoetin alfa–related stroke.
Clinical Trial Registration—http://www.clinicaltrials.gov. Unique identifier: NCT00093015.
(Circulation. 2011;124:2903-2908.)
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The presence of anemia has been consistently associatedwith a higher risk of cardiovascular (CV) events in
adjusted analyses from both epidemiological observations
and clinical trials encompassing broad and diverse popula-
tions.1–7 Among patients with type 2 diabetes mellitus and
nondialysis chronic kidney disease (CKD), those with anemia
had a 60% to 90% greater adjusted relative risk of death,
myocardial infarction, or stroke in a pooled analysis of 4
major epidemiological cohorts.8 However, in the placebo-
controlled Trial to Reduce Cardiovascular Events With
Aranesp Therapy (TREAT),9 correction of anemia in patients
with type 2 diabetes mellitus and nondialysis CKD with the
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erythropoiesis-stimulating agent (ESA) darbepoetin alfa had
no effect, overall, on the composite end point of death or
nonfatal CV events. Moreover, we observed a statistically
significant and clinically important increase in the rate of
stroke in patients assigned to darbepoetin alfa.
Editorial see p 2805
Clinical Perspective on p 2908
To aid clinical decision making in prescribing ESA ther-
apy, we examined baseline characteristics and postrandom-
ization factors, including blood pressure, platelet count,
achieved hemoglobin level, and treatment dose, which might
explain the heightened risk of stroke associated with darbe-
poetin alfa.
Methods
The Trial to Reduce Cardiovascular Events With Aranesp Therapy
was a randomized, double-blind, placebo-controlled trial of patients
with type 2 diabetes mellitus, nondialysis CKD (estimated glomer-
ular filtration rate [eGFR] of 20–60 mL  min1  1.73 m2) and
anemia (hemoglobin level 11 g/dL) designed to determine whether
treatment with darbepoetin alfa would reduce the risk of (1) a
cardiovascular composite of death, myocardial infarction, heart
failure, stroke, or hospitalization for myocardial ischemia, (2) a renal
composite of death or end-stage renal disease (initiation of dialysis),
or both. Subjects were randomly assigned to receive either darbepo-
etin alfa to attempt to achieve a hemoglobin level of 13 g/dL or
placebo with rescue darbepoetin alfa if their hemoglobin level was
9 g/dL. Hemoglobin levels and vital signs were assessed every 2
weeks during the titration period and monthly thereafter. The
rationale and design,10 baseline characteristics,11 and the primary
results9 of the trial have been published. The Trial to Reduce
Cardiovascular Events With Aranesp Therapy is registered at
http://www.clinicaltrials.gov, unique identifier: NCT00093015. The
randomization groups were similar without any clinically meaning-
ful baseline differences except for history of heart failure, which was
more prevalent in the placebo arm.
All potential end points, including stroke, were prospectively
defined and adjudicated by a central committee that was blinded to
treatment assignment and hemoglobin levels. Stroke was defined as
a focal neurological deficit of sudden onset lasting 24 hours or
resulting in death and which was not due to another readily
identifiable cause (ie, brain tumor or trauma). Neuroimaging was not
mandated by protocol and performed as deemed necessary for
clinical reasons. Where available, imaging reports were used to
categorize stroke as hemorrhagic or nonhemorrhagic (cases without
imaging results were considered as nonhemorrhagic strokes). For
patients who experienced 1 stroke, only the first stroke was used in
this analysis.
Statistical Analysis
Distributions of baseline characteristics are presented as median
(interquartile range) for the overall population. In this posthoc
analysis, univariate comparisons for baseline characteristics between
patients who experienced a stroke and those who did not were
performed with 2-sample Wilcoxon rank-sum test or the Fisher exact
test. History of cardiovascular diseases was derived from the clinical
database as previously used and a history of stroke or transient
ischemic attack was part of the definition of history of cardiovascular
diseases.9 The urinary protein-to-creatinine ratio was log trans-
formed. The cumulative incidence function of stroke was presented
by treatment arm and history of stroke, and the treatment effect was
estimated using a proportional subdistribution hazards approach.12
Potential baseline predictors of stroke were selected on the basis of
clinically known risk factors for stroke as well as factors identified
in the univariate analysis. Logistic regression was used for outcomes
analysis. A stepwise forward selection procedure (P0.10) was
performed to help build a multivariable model. Variables considered
clinically relevant that were not statistically significant were retained
in the model. In addition, interaction among treatment allocation and
statistically significant baseline variables was prospectively
evaluated.
To assess whether the increased risk of stroke in patients treated
with darbepoetin alfa could be explained by postrandomization
factors, we conducted a nested-case control analysis within each
treatment arm. Using the baseline variables selected in the logistic
regression model, a propensity score for stroke was developed within
each treatment arm separately to select subjects, free of stroke by the
end of the trial, who would serve as controls. Within each treatment
arm, every patient experiencing a stroke (case) was matched to 10
controls that had an equivalent duration of follow-up (1:10 nearest
neighbor propensity-score matching).
Postrandomization factors studied included hemoglobin level,
blood pressure, platelet count, and dose of darbepoetin alfa. For each
factor, we compared the latest value available in the 3 months
preceding the stroke (or equivalent parallel period for controls)
between cases and controls in each treatment arm separately using
generalized Hodges-Lehmann median difference test for clustered
data.13 In additional sensitivity analyses, we compared the average of
the latest available values (up until the stroke or the equivalent period
for controls), the highest value in the latest 3 months, and highest
during entire follow-up. We also varied the case-control ratio (1:1,
1:5, and 1:15). A P value of 0.05 was considered statistically
significant. All analyses were performed with Stata 11.1 (StataCorp,
College Station, TX), and R 2.10.2 (R Project for Statistical
Computing, Vienna, Austria).
Results
Over a median follow-up period of 29.1 months, 154/4038
(3.8%) of patients randomized had a stroke, 53/2026 (2.6%,
1.1 per 100 patient-years) in the placebo arm and 101/2012
(5.0%, 2.1 per 100 patient-years) in the darbepoetin alfa arm;
hazard ratio 1.92, 95% confidence interval, 1.38 to 2.68. Of
the total of 154 strokes, 133 (86.4%) were categorized as
nonhemorrhagic (ischemic cause: 112 [72.7%]; unknown: 21
[13.6%]) and 21 (13.6%) as hemorrhagic. Each type of stroke
was numerically more frequent in the darbepoetin alfa group
compared with the placebo group: nonhemorrhagic, 87
(4.3%) versus 46 (2.3%), and hemorrhagic, 14 (0.7%) versus
7 (0.3%), respectively.
Baseline Predictors of Stroke
In addition to treatment assignment to darbepoetin alfa,
univariate predictors of stroke included history of cardiovas-
cular diseases, specifically history of stroke, or transient
ischemic attack. Although a history of stroke or transient
ischemic attack was part of the definition of history of
cardiovascular diseases, both remained statistically signifi-
cantly associated with incident stroke during follow-up.
Patients who had a stroke during the trial also had higher
urinary protein–to-creatinine ratio and glycohemoglobin and
lower body mass index (BMI), eGFR, serum albumin, hemo-
globin, and transferrin saturation. Imbalances in baseline
medication use were also found, with stroke patients more
likely to be on a vitamin K antagonists or insulin and less
likely to be on an oral hypoglycemic agent (Table 1). In a
multivariate logistic regression model of predictors of stroke
(Table 2), the 2 predictors with the highest z score were
assignment to darbepoetin alfa therapy (odds ratio 2.08; 95%
confidence interval, 1.47–2.94), and a history of stroke or
transient ischemic attack (odds ratio 2.00; 95% confidence
interval, 1.36–2.94). Other independent baseline predictors
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included urinary protein–to-creatinine ratio, insulin therapy,
history of CV disease, and lower serum hemoglobin level or
BMI.
We tested whether any of the independent baseline predic-
tors of stroke modified the risk of this event related to
treatment with darbepoetin alfa. None of the interaction tests
were statistically significant (all were P0.1). In particular,
although the darbepoetin alfa–related risk of stroke was
higher in patients with prior stroke (HR 2.99; 95% confidence
interval, 1.40–6.36) than in those without prior stroke (HR
1.61; 95% confidence interval, 1.14–2.41), the test for
interaction was not significant (P0.25, the Figure).
Table 1. Baseline Characteristics
Stroke No Stroke
Variable N154 (3.8%) N3884 (96.2%) P
Darbepoetin alfa 101 (65.6) 1911 (49.2) 0.0001
Age, y 69 (62, 76) 68 (60, 75) 0.08
Male gender 71 (46.1) 1655 (42.6) 0.41
Race 0.02
White 104 (67.5) 2466 (63.5)
Black 37 (24.0) 778 (20.0)
Other 13 (8.4) 640 (16.5)
Known duration of diabetes
mellitus, months
195 (121, 279) 184 (99, 259) 0.14
BMI, kg/m2 29.0 (25.3, 34.1) 30.3 (26.3, 35.2) 0.03
Current smoking 8 (5.2) 196 (5.0) 0.85
History of CV disease 123 (79.9) 2519 (64.9) 0.0001
Coronary artery disease 79 (51.3) 1712 (44.1) 0.08
Heart failure 58 (37.7) 1289 (33.2) 0.26
Myocardial infarction 35 (22.7) 706 (18.2) 0.17
Stroke 36 (23.4) 411 (10.6) 0.0001
Transient ischemic attack 18 (11.7) 247 (6.4) 0.02
Peripheral arterial disease 35 (22.7) 744 (19.2) 0.30
Atrial fibrillation 21 (13.7) 404 (10.4) 0.23
SBP, mm Hg 138 (127, 150) 136 (122, 148) 0.17
DBP, mm Hg 74 (64, 80) 70 (64, 80) 0.23
Heart rate, bpm 72 (66, 80) 72 (64, 80) 0.08
eGFR, ml  min1  1.73 m2 31 (24, 41) 34 (26, 43) 0.05
Ratio of total protein (mg/dL) to
creatinine (mg/dL) in urine
0.7 (0.2, 2.6) 0.4 (0.1, 1.8) 0.001
Serum albumin, g/dL 3.9 (3.6, 4.2) 4.0 (3.7, 4.3) 0.01
Glycated hemoglobin, % 7.2 (6.5, 8.2) 7.0 (6.2, 8.0) 0.05
Hemoglobin, g/dL 10.2 (9.5, 10.9) 10.4 (9.8, 10.9) 0.01
Platelets, 109/L 241 (202, 296) 243 (198, 293) 0.51
Ferritin, ng/mL 152 (76, 257) 132 (66, 257) 0.13
Transferrin saturation, % 24 (20, 31) 23 (18, 28) 0.01
Total cholesterol, mg/dL 171 (148, 213) 169 (142, 201) 0.18
LDL, mg/dL 88 (68, 123) 85 (63, 111) 0.08
Insulin 89 (57.8) 1900 (48.9) 0.03
Oral iron therapy 64 (41.6) 1644 (42.3) 0.85
Oral hypoglycemic agent 70 (45.5) 2223 (57.2) 0.01
Statin or lipid-lowering agent 88 (57.1) 2507 (64.5) 0.07
Aspirin or antiplatelet agent 77 (50.0) 1873 (48.2) 0.68
Vitamin K antagonist 18 (11.7) 259 (6.7) 0.02
Values presented as median (IQR) or N (%). BMI indicates body mass index;
CV, cardiovascular; SBP, systolic blood pressure; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; and LDL, low-density lipoprotein.
Comparisons testing with nonparametric Wilcoxon test for continuous
variables and Fisher exact test for categorical variables.
Table 2. Multivariate Baseline Predictors of Stroke
Variable OR z Score P 95 % CI
Darbepoetin alfa 2.08 4.16 0.001 1.47 to 2.94
History of stroke/TIA 2.00 3.53 0.001 1.36 to 2.94
Log protein:creatinine ratio 1.21 2.98 0.003 1.07 to 1.37
Insulin use 1.48 2.23 0.026 1.05 to 2.09
History of CV disease 1.60 2.08 0.038 1.03 to 2.49
Hb, 1 g/dL down 1.18 2.02 0.043 1.01 to 1.39
BMI, 1 kg/m2 down 1.03 2.02 0.044 1.00 to 1.05
Age, 10 y up 1.20 1.95 0.051 1.00 to 1.44
Heart rate, bpm up 1.01 1.76 0.079 1.00 to 1.03
Statin or other lipid-lowering
agent
0.74 1.73 0.084 0.53 to 1.04
Vitamin K antagonist 1.66 1.66 0.097 0.91 to 3.02
Black race (vs white) 1.30 1.28 0.201 0.87 to 1.95
Other race (vs white) 0.49 2.32 0.020 (0.27 to 0.89)
eGFR, 1 mL  min1  1.73 m2
down
1.01 0.90 0.370 (0.99 to 1.02)
History of atrial fibrillation 0.90 0.36 0.722 (0.51 to 1.58)
SBP, 10 mm Hg down 1.01 0.17 0.869 (0.92 to 1.10)
C-statistic0.72 (95% CI 0.68–0.76). This was not statistically different
from a more parsimonious model that included only treatment assignment,
history of stroke or transient ischemic attack, log protein:creatinine ratio,
insulin therapy, history of CV disease, serum hemoglobin level, BMI, age, and
race (C-statistic0.70; 95% CI, 0.66–0.74).
OR indicates odds ratio; CI, confidence interval; TIA, transient ischemic
attack; CV, cardiovascular; Hb, hemoglobin; BMI, body mass index; bpm, beats
per minute; eGFR, estimated glomerular filtration rate; and SBP, systolic blood
pressure.
Variables not retained in multivariate model that were significant in
univariate analyses: serum albumin, glycated hemoglobin, and transferrin
saturation.
Figure. Cumulative incidence function of stroke by treatment
arm and history of stroke. HR indicates hazard ratio.
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In a treatment-stratified, nested, case-control analysis, there
was no difference between patients who experienced a stroke
and those who did not in terms of latest blood pressure value,
hemoglobin level, platelet count, or dose of darbepoetin alfa
(Table 3). Among patients assigned to darbepoetin alfa
experiencing a stroke (n86), the last-measured blood pres-
sure in the 90 days preceding the event was 135/72 mm Hg
compared with 134/72 mm Hg over the same time interval in
patients who did not have a stroke (n923; P0.50). In
patients in the darbepoetin alfa–treated group experiencing a
stroke, the last-measured hemoglobin concentration in the 90
days preceding stroke was 12.3 mg/dL compared with 12.5
mg/dL in darbepoetin alfa–treated patients without a stroke
(P0.09).
In the placebo-treated group, there were also no differences
in any of the evaluated factors between those with and
without a stroke (Table 3). Moreover, the proportion of
patients receiving rescue treatment with darbepoetin alfa was
not different between cases with strokes and their nonstroke
controls (14% versus 19%, P0.54; Table 3). Postrandom-
ization iron parameters also did not significantly differ
between subjects with and without stroke. Within each
treatment arm, the latest ferritin and transferrin saturation
values preceding a stroke event were similar among cases and
controls. The number of subjects being treated with intrave-
nous iron preceding the event was similar among cases and
controls (darbepoetin alfa: cases: 15/101 [14.9%] versus
controls: 16/101 [15.8%] and placebo: cases: 10/52 [19.2%]
versus controls: 7/52 [13.5%]).
Additional sensitivity analyses examining the latest, high-
est, and average value of blood pressure, hemoglobin, platelet
count, and dose of darbepoetin alfa in the 90 days preceding
the event (or during the entire follow-up) each produced
similar results, as did varying the case-to-control ratio. In
each analysis, the postrandomization blood pressure, hemo-
globin level, platelet count, and dose of darbepoetin alfa were
similar between the cases with a stroke and their nonstroke
controls (see online-only Data Supplement).
Discussion
We found that in this cohort of patients with type 2 diabetes
mellitus, nondialysis CKD, and anemia, allocation to darbe-
poetin alfa was associated with a statistically significant
doubling of the risk of stroke. The risk of stroke related to
darbepoetin alfa did not appear to be associated with any
baseline characteristic. Furthermore, this risk was not medi-
ated by postrandomization factors previously implicated as
mechanisms of ESA-related adverse outcomes,14,15 including
increase in hemoglobin level, blood pressure, or platelet
number, and was not related to dose of darbepoetin alfa.
Although a number of baseline characteristics predicted
risk of stroke in the overall TREAT population, none of these
modified the risk of stroke related to darbepoetin alfa. In
particular, history of stroke did not modify the risk related to
darbepoetin (ie, the risk of stroke with this ESA was in-
creased both in patients with and without a prior history of
stroke). Interestingly, we observed an inverse relationship
between BMI and risk of stroke where subjects with lower
BMI at baseline were at higher risk of stroke. This association
was recently described in a cohort of subjects with diabetes
mellitus16 and may carry important prognostic information,
given that lower BMI at the time of stroke was also associated
with a higher risk of death.17
Of the postrandomization variables examined, increase in
hemoglobin has most often been proposed as a mediator of
ESA-related CV risk, in part because it raises blood viscosity
and vascular resistance and may increase blood pressure.15,18
The initial rapid rise in hemoglobin concentration, the so-
called ramp phase, has been of particular concern.19 However,
we did not find any association between stroke and average
achieved hemoglobin, change in hemoglobin, or peak hemo-
globin during varying follow-up periods in either darbepoetin
alfa–treated or placebo-treated patients. In fact, the achieved
hemoglobin level was lower in the stroke cases than in the
nonstroke controls although this difference was not statisti-
cally significant. Furthermore, there was a marked temporal
disassociation between the early rise in hemoglobin and the
late augmentation in stroke rates,9 which does not support
concerns about the ramp phase of treatment.19
Although earlier studies in patients with severe anemia
suggested that blood pressure may increase in up to one third
of patients treated with recombinant human erythropoietin,
there was no difference in systolic blood pressure between the
treatment groups in TREAT, and a 1.7-mm Hg difference in
Table 3. Latest Values Before Stroke (1:10 Matching)
Most Recent Value













N Median (IQR) N Median (IQR) N Median (IQR) N Median (IQR)
Systolic BP (mm Hg) 86 135 (120, 150) 923 134 (121, 145) 0.98 44 136 (122, 148) 468 137 (124, 150) 0.52
Diastolic BP, mm Hg 86 72 (64, 80) 923 72 (66, 80) 0.62 44 70 (63, 80) 468 72 (64, 80) 0.76
Hemoglobin, mg/dL 80 12.3 (11.1, 13.1) 864 12.5 (11.7, 13.2) 0.10 42 10.4 (9.4, 10.8) 438 10.4 (9.7, 11.3) 0.20
Platelet count, 1000/dL 38 230 (172, 301) 470 225 (185, 281) 0.87 26 225 (182, 291) 253 236 (194, 281) 0.50
Darbepoetin alfa dose, g/mo 80 150 (100, 300) 866 150 (80, 300) 0.79 42 0 (0, 0) 436 0 (0, 0) 0.40
All controls were pooled from patients who were free of stroke by the end of the trial. Data presented as median (IQR). Varying sample size contingent on available
data for particular variable. All pairwise comparisons tested with generalized Hodges-Lehmann median difference test for clustered data.
*Rescue darbepoetin alfa in placebo arm, expressed as n/N (%), was 6/43 (14) in stroke cases and 82/434 (19) in no stroke controls (P0.54).
IQR indicates interquartile range; BP, blood pressure.
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diastolic pressure was observed (higher in the darbepoetin
alfa arm).9 More importantly, in the present analysis, there
was no association between postrandomization blood pres-
sure and the incidence of stroke despite extensive analyses.
Specifically, the latest systolic or diastolic pressure preceding
stroke in cases (or during the equivalent period in nonstroke
controls) was not different between cases and controls within
each treatment arm. The same was true for mean and highest
pressures measured preceding stroke or at any time during the
entire follow-up period. In addition, as previously reported,
there was no statistically significant difference between
treatment groups in reporting of hypertension as an adverse
event by investigators: 24.4% in patients randomized to
darbepoetin alfa compared with 22.0% in those assigned to
placebo (P0.07).9
Increases in platelet count, reactivity, or both may also
occur after ESA administration, and could promote a pro-
thrombotic milieu.20 In patients undergoing dialysis in the
Normal-Hematocrit study, the risk of thrombosis affecting the
vascular access site was increased in the higher-hemoglobin
target group compared with the lower-hemoglobin target
group: 243 patients (39%) versus 176 patients (29%),
P0.001.21 In TREAT, thromboembolic events were also
reported more frequently in patients treated with darbepoetin
alfa compared with placebo (venous: 2.0% versus 1.1%,
P0.02; arterial: 8.9% versus 7.1%, P0.04).9 In the current
analyses, however, there was no association between various
assessments of platelet count and incident stroke in either
treatment arm.
Dose-related nonerythropoietic toxicity has also been in-
voked as a possible mechanism for ESA-related risk.22 In the
German Multicenter Erythropoietin Stroke Trial, there was an
increase in mortality among acute-stroke patients randomized
to just 3 doses of epoetin alfa given over 48 hours.23 In
TREAT, the median monthly dose of darbepoetin alfa admin-
istered to patients who had a stroke was not different than the
dose administered to the matched nonstroke controls.
Furthermore, in the placebo arm, there was no relation
between the risk of stroke and use of darbepoetin alfa as
rescue therapy. We have also reported that poor initial
hemoglobin response to an ESA (despite escalating dosing)
was associated with increased risk of death or cardiovascular
events in TREAT.24 However, the rate of stroke was not
higher in patients with a poor initial hemoglobin response to
darbepoetin alfa therapy.
Some limitations of this analysis need to be acknowledged.
The increase in stroke with darbepoetin alfa could be a chance
finding. However, the similar observation in the study by
Parfrey and colleagues25 and the relatively large number of
strokes in TREAT argue against this. Furthermore, given the
clinical importance of stroke, it is safer to adopt a conserva-
tive approach and assume this increased risk to be actual.26
Subtle differences in blood pressure between treatment
groups might have been detected using more intensive meth-
ods such as ambulatory monitoring. Greater modification of
antihypertensive medication in the darbepoetin alfa group by
investigators might also have concealed an increase in blood
pressure in the treatment group compared with placebo.
Although platelet count did not differ between treatments,
darbepoetin alfa might have changed platelet reactivity,
which was not measured. Although we did not have complete
or comprehensive imaging data on stroke type or information
on stroke severity and outcome, this end point was prospec-
tively defined and centrally adjudicated without knowledge
of randomization arm or hemoglobin levels.
In summary, darbepoetin alfa doubled the risk of stroke in
patients with type 2 diabetes mellitus, nondialysis CKD, and
anemia. No baseline characteristic was associated with dar-
bepoetin alfa–related risk of stroke. Similarly, despite exten-
sive analyses of postrandomization blood pressure, hemoglo-
bin, platelet count, and dose of treatment, no factor previously
identified as a potential mechanism for ESA-related cardio-
vascular risk explained the increase in risk of stroke observed
with darbepoetin alfa. Measurement of these readily available
follow-up parameters cannot be used to mitigate the risk of
darbepoetin alfa–related stroke.
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CLINICAL PERSPECTIVE
Although anemia has been associated with higher mortality and morbidity in subjects with diabetes mellitus and
nondialysis chronic kidney disease, treatments with erythropoiesis-stimulating agents have not led to improvements in
prognosis. In the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), a concerning increase in the risk
of darbepoetin alfa–related stroke was observed. We examined the role of baseline predictors and postrandomization
factors that might explain this heightened risk of stroke with darbepoetin alfa. We found that in this cohort of patients with
type 2 diabetes mellitus, nondialysis chronic kidney disease, and anemia, the risk of stroke related to darbepoetin alfa did
not appear to be associated with any baseline characteristic. Despite extensive sensitivity analyses, this risk did not seem
to be mediated by postrandomization factors previously implicated as mechanisms of erythropoiesis-stimulating
agent–related adverse outcomes, including increase in hemoglobin level, blood pressure, or platelet number, and was not
related to dose of darbepoetin alfa. Therefore, clinicians cannot rely on monitoring these readily available follow-up
parameters to mitigate the risk of darbepoetin alfa–related stroke.
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Stroke in Patients with Type 2 Diabetes, Chronic Kidney Disease and Anemia 
Treated with Darbepoetin Alfa. The TREAT Experience 
 
 




Abbreviations	  used	  in	  tables:	  
SBP:	  systolic	  blood	  pressure	  (mmHg)	  
DBP:	  diastolic	  blood	  pressure	  (mmHg)	  
Hb:	  hemoglobin	  (g/dL)	  
PLT:	  platelet	  count	  (109/L)	  
	  
Notes:	  	  
All	  controls	  were	  pooled	  from	  patients	  who	  were	  stroke	  free	  by	  the	  end	  of	  the	  trial.	  
All	  pairwise	  comparisons	  tested	  with	  generalized	  Hodges-­‐Lehmann	  median	  difference	  test	  for	  
clustered	  data.	  
Sample	  size	  in	  each	  cell	  varied	  contingent	  on	  available	  data	  for	  particular	  variable.	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Table 1A: Change from baseline value of post-randomization factors for cases and controls (1:1 matching) in each 
treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  





N	  =	  101	  





N	  =	  52	  
P	  value	  
Highest	  SBP	   N	  =	  101	   N	  =	  101	   0.84	   N	  =	  52	   N	  =	  52	   0.12	  
	   21	  (5,	  34)	   18	  (5,	  40)	   	   14	  (0,	  31)	   21	  (5,	  32)	   	  
Highest	  DBP	   N	  =	  101	   N	  =	  101	   0.59	   N	  =	  52	   N	  =	  52	   0.15	  
	   10	  (4,	  19)	   11	  (5,	  20)	   	   6	  (0,	  15)	   10	  (0,	  18)	   	  
Latest	  SBP	   N	  =	  101	   N	  =	  101	   0.65	   N	  =	  52	   N	  =	  52	   0.17	  
	   -­‐1	  (-­‐14,	  11)	   0	  (-­‐16,	  13)	   	   0	  (-­‐8,	  18)	   -­‐2	  (-­‐16,	  10)	   	  
Latest	  DBP	   N	  =	  101	   N	  =	  101	   0.66	   N	  =	  52	   N	  =	  52	   0.64	  
	   0	  (-­‐10,	  8)	   0	  (-­‐10,	  7)	   	   0	  (-­‐4,	  5)	   0	  (-­‐8,	  6)	   	  
Highest	  Hb	   N	  =	  101	   N	  =	  100	   0.37	   N	  =	  52	   N	  =	  52	   0.40	  
	   3.8	  (2.6,	  4.5)	   4.0	  (2.8,	  4.8)	   	   0.9	  (0.3,	  1.6)	   1.2	  (0.4,	  2.0)	   	  
Latest	  Hb	   N	  =	  101	   N	  =	  100	   0.78	   N	  =	  52	   N	  =	  52	   0.36	  
	   1.9	  (0.9,	  2.8)	   1.9	  (0.6,	  3.0)	   	   0.0	  (-­‐0.5,	  0.7)	   0.0	  (-­‐1.1,	  0.7)	   	  
Highest	  Dose	   N	  =	  101	   N	  =	  100	   0.78	   N	  =	  52	   N	  =	  52	   0.56	  
	   100	  (40,	  400)	   160	  (35,	  310)	   	   0	  (0,	  15)	   0	  (0,	  30)	   	  
Latest	  Dose	   N	  =	  101	   N	  =	  100	   0.61	   N	  =	  52	   N	  =	  52	   0.46	  
	   20	  (-­‐30,	  180)	   50	  (-­‐20,	  180)	   	   0	  (0,	  0)	   0	  (0,	  0)	   	  
Highest	  PLT	   N	  =	  101	   N	  =	  98	   0.88	   N	  =	  52	   N	  =	  52	   0.89	  
	   5	  (0,	  33)	   6	  (0,	  36)	   	   0	  (0,	  37)	   0	  (0,	  18)	   	  
Latest	  PLT	   N	  =	  101	   N	  =	  98	   0.96	   N	  =	  52	   N	  =	  52	   0.99	  
	   -­‐3	  (-­‐33,	  21)	   0	  (-­‐24,	  13)	   	   0	  (-­‐31,	  2)	   0	  (-­‐32,	  2)	   	  
 
Table 1B: Average value over entire follow-up of post-randomization factors for cases and controls (1:1 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  







N	  =	  101	  





N	  =	  52	  
P	  
value	  
Average	  SBP	   N	  =	  101	   N	  =	  101	   0.50	   N	  =	  52	   N	  =	  52	   0.62	  
	   133	  (124,	  140)	   132	  (126,	  146)	   	   137	  (127,	  146)	   138	  (133,	  145)	   	  
Average	  DBP	   N	  =	  101	   N	  =	  101	   0.55	   N	  =	  52	   N	  =	  52	   0.94	  
	   73	  (67,	  78)	   74	  (67,	  79)	   	   73	  (68,	  79)	   75	  (67,	  78)	   	  
Average	  Hb	   N	  =	  101	   N	  =	  100	   0.01	   N	  =	  52	   N	  =	  52	   0.38	  
	   12.3	  (11.6,	  12.6)	   12.1	  (11.3,	  12.5)	   	   10.4	  (9.7,	  11.0)	   10.2	  (9.6,	  10.7)	   	  
Average	  weekly	  dose	   N	  =	  101	   N	  =	  100	   0.92	   N	  =	  52	   N	  =	  52	   0.28	  
	   43	  (10,	  139)	   54	  (8,	  125)	   	   0	  (0,	  2)	   0	  (0,	  4)	   	  
Average	  PLT	   N	  =	  101	   N	  =	  99	   0.96	   N	  =	  52	   N	  =	  52	   0.43	  
	   240	  (198,	  277)	   245	  (197,	  295)	   	   228	  (189,	  263)	   245	  (200,	  278)	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Table 1C: Change from baseline value of post-randomization factors for cases and controls (1:1 matching) in each 
treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  
Change	  from	  baseline	  to	  






N	  =	  101	  





N	  =	  52	  
P	  value	  
Highest	  SBP90	   N	  =	  92	   N	  =	  86	   0.71	   N	  =	  46	   N	  =	  44	   0.81	  
	   7	  (-­‐2,	  20)	   7	  (0,	  23)	   	   0	  (-­‐2,	  20)	   0	  (-­‐5,	  23)	   	  
Highest	  DBP90	   N	  =	  92	   N	  =	  86	   0.37	   N	  =	  46	   N	  =	  44	   0.49	  
	   6	  (0,	  11)	   6	  (0,	  14)	   	   0	  (0,	  5)	   0	  (0,	  11)	   	  
Latest	  SBP90	   N	  =	  92	   N	  =	  86	   0.80	   N	  =	  46	   N	  =	  44	   0.35	  
	   -­‐1	  (-­‐14,	  12)	   0	  (-­‐16,	  13)	   	   0	  (-­‐8,	  17)	   -­‐1	  (-­‐15,	  8)	   	  
Latest	  DBP90	   N	  =	  92	   N	  =	  86	   0.55	   N	  =	  46	   N	  =	  44	   0.83	  
	   0	  (-­‐10,	  8)	   0	  (-­‐10,	  8)	   	   0	  (-­‐8,	  5)	   -­‐1	  (-­‐8,	  4)	   	  
Highest	  Hb90	   N	  =	  87	   N	  =	  80	   0.51	   N	  =	  42	   N	  =	  42	   0.85	  
	   2.7	  (2.0,	  3.6)	   2.9	  (1.9,	  3.9)	   	   0.6	  (0.0,	  1.1)	   0.6	  (0.0,	  1.2)	   	  
Latest	  Hb90	   N	  =	  87	   N	  =	  80	   0.81	   N	  =	  42	   N	  =	  42	   0.67	  
	   2.0	  (0.9,	  2.8)	   2.2	  (0.7,	  3.2)	   	   0.1	  (-­‐0.4,	  0.7)	   0.0	  (-­‐0.4,	  0.8)	   	  
Highest	  PLT90	   N	  =	  51	   N	  =	  38	   0.85	   N	  =	  28	   N	  =	  26	   0.83	  
	   -­‐14	  (-­‐35,	  12)	   -­‐3	  (-­‐38,	  24)	   	   0	  (-­‐22,	  0)	   0	  (-­‐27,	  0)	   	  
Latest	  PLT90	   N	  =	  51	   N	  =	  38	   0.87	   N	  =	  28	   N	  =	  26	   0.83	  
	   -­‐14	  (-­‐36,	  12)	   -­‐3	  (-­‐42,	  24)	   	   0	  (-­‐22,	  0)	   0	  (-­‐27,	  0)	   	  
	  
Table 1D: Average value over most recent 90 days of post-randomization factors for cases and controls (1:1 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  
Average	  value	  over	  	  






N	  =	  101	  





N	  =	  52	  
P	  
value	  
Average	  SBP90	   N	  =	  92	   N	  =	  86	   0.60	   N	  =	  46	   N	  =	  44	   0.62	  
	   132	  (124,	  151)	   136	  (127,	  146)	   	   135	  (127,	  154)	   137	  (124,	  150)	   	  
Average	  DBP90	   N	  =	  92	   N	  =	  86	   0.48	   N	  =	  46	   N	  =	  44	   0.94	  
	   73	  (66,	  79)	   75	  (67,	  81)	   	   72	  (68,	  80)	   74	  (64,	  79)	   	  
Average	  Hb90	   N	  =	  87	   N	  =	  80	   0.05	   N	  =	  42	   N	  =	  42	   0.90	  
	   12.6	  (11.8,	  13.2)	   12.2	  (11.3,	  12.9)	   	   10.4	  (9.6,	  11.0)	   10.3	  (9.8,	  10.9)	   	  
Average	  PLT90	   N	  =	  51	   N	  =	  39	   0.50	   N	  =	  28	   N	  =	  26	   0.73	  
	   239	  (182,	  293)	   230	  (172,	  301)	   	   210	  (179,	  264)	   225	  (182,	  291)	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Table 2A: Change from baseline value of post-randomization factors for cases and controls (1:5 matching) in each 
treatment arm.  
 
	   Darbepoetin	  alfa	   	   Placebo	   	  















N	  =	  52	  
P	  
value	  
Highest	  SBP	   N	  =	  505	   N	  =	  101	   0.70	   N	  =	  260	   N	  =	  52	   0.08	  
	   20	  (10,	  36)	   18	  (5,	  40)	   	   14	  (0,	  30)	   21	  (5,	  31.5)	   	  
Highest	  DBP	   N	  =	  505	   N	  =	  101	   0.65	   N	  =	  260	   N	  =	  52	   0.58	  
	   12	  (5,	  20)	   11	  (5,	  20)	   	   9	  (0,	  15)	   10	  (0,	  18)	   	  
Latest	  SBP	   N	  =	  505	   N	  =	  101	   0.80	   N	  =	  260	   N	  =	  52	   0.40	  
	   -­‐2	  (-­‐14,	  10)	   0	  (-­‐16,	  13)	   	   0	  (-­‐10,	  10)	   -­‐1.5	  (-­‐15.5,	  10)	   	  
Latest	  DBP	   N	  =	  505	   N	  =	  101	   0.85	   N	  =	  260	   N	  =	  52	   0.25	  
	   0	  (-­‐8,	  8)	   0	  (-­‐10,	  7)	   	   0	  (-­‐4.5,	  5)	   0	  (-­‐8,	  6)	   	  
Highest	  Hb	   N	  =	  504	   N	  =	  100	   0.97	   N	  =	  259	   N	  =	  52	   0.75	  
	   3.8	  (3.0,	  4.7)	   4.0	  (2.8,	  4.8)	   	   1.2	  (0.3,	  2.2)	   1.2	  (0.4,	  2.0)	   	  
Latest	  Hb	   N	  =	  504	   N	  =	  100	   0.12	   N	  =	  259	   N	  =	  52	   0.11	  
	   2.1	  (1.2,	  3.0)	   1.9	  (0.6,	  3.0)	   	   0.1	  (-­‐0.6,	  1.1)	   0.0	  (-­‐1.1,	  0.7)	   	  
Highest	  Dose	   N	  =	  505	   N	  =	  100	   0.50	   N	  =	  259	   N	  =	  52	   0.57	  
	   140	  (40,	  440)	   160	  (35,	  310)	   	   0	  (0,	  20)	   0	  (0,	  30)	   	  
Latest	  Dose	   N	  =	  505	   N	  =	  100	   0.67	   N	  =	  259	   N	  =	  52	   0.97	  
	   30	  (-­‐40,	  200)	   50	  (-­‐20,	  180)	   	   0	  (0,	  0)	   0	  (0,	  0)	   	  
Highest	  PLT	   N	  =	  504	   N	  =	  98	   0.83	   N	  =	  258	   N	  =	  52	   0.48	  
	   6	  (0,	  37)	   6	  (0,	  36)	   	   0	  (0,	  31)	   0	  (0,	  18)	   	  
Latest	  PLT	   N	  =	  504	   N	  =	  98	   0.87	   N	  =	  258	   N	  =	  52	   0.34	  
	   0	  (-­‐34,	  14)	   0	  (-­‐24,	  13)	   	   0	  (-­‐22,	  8)	   0	  (-­‐32,	  2)	   	  
 
Table 2B: Average value over entire follow-up of post-randomization factors for cases and controls (1:5 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  















N	  =	  52	  
P	  
value	  
Average	  SBP	   N	  =	  505	   N	  =	  101	   0.88	   N	  =	  260	   N	  =	  52	   0.43	  
	   134	  (127,	  143)	   132	  (126,	  146)	   	   137	  (129,	  146)	   138	  (133,	  145)	   	  
Average	  DBP	   N	  =	  505	   N	  =	  101	   0.94	   N	  =	  260	   N	  =	  52	   0.31	  
	   73	  (68,	  78)	   74	  (67,	  79)	   	   72	  (66,	  78)	   75	  (67,	  78)	   	  
Average	  Hb	   N	  =	  505	   N	  =	  100	   <0.001	   N	  =	  259	   N	  =	  52	   0.04	  
	   12.3	  (11.8,	  12.6)	   12.1	  (11.3,	  12.5)	   	   10.4	  (9.9,	  11.1)	   10.2	  (9.6,	  10.7)	   	  
Average	  weekly	  dose	   N	  =	  505	   N	  =	  100	   0.68	   N	  =	  259	   N	  =	  52	   0.18	  
	   56	  (9,	  142)	   54	  (8,	  125)	   	   0	  (0,	  2)	   0	  (0,	  4)	   	  
Average	  PLT	   N	  =	  505	   N	  =	  99	   0.24	   N	  =	  258	   N	  =	  52	   0.67	  
	   230	  (188,	  272)	   245	  (197,	  295)	   	   238	  (198,	  279)	   245	  (200,	  278)	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Table 2C: Change from baseline value of post-randomization factors for cases and controls (1:5 matching) in each 
treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  
Change	  from	  
baseline	  to	  














N	  =	  52	  
P	  
value	  
Highest	  SBP90	   N	  =	  463	   N	  =	  86	   0.43	   N	  =	  234	   N	  =	  44	   0.61	  
	   6	  (-­‐3,	  20)	   6.5	  (0,	  23)	   	   1	  (0,	  20)	   0	  (-­‐4.5,	  23)	   	  
Highest	  DBP90	   N	  =	  463	   N	  =	  86	   0.33	   N	  =	  234	   N	  =	  44	   0.61	  
	   5	  (0,	  12)	   6	  (0,	  14)	   	   2	  (0,	  10)	   0	  (0,	  11)	   	  
Latest	  SBP90	   N	  =	  463	   N	  =	  86	   0.66	   N	  =	  234	   N	  =	  44	   0.47	  
	   -­‐2	  (-­‐14,	  10)	   0	  (-­‐16,	  13)	   	   0	  (-­‐10,	  10)	   -­‐0.5	  (-­‐14.5,	  7.5)	   	  
Latest	  DBP90	   N	  =	  463	   N	  =	  86	   0.74	   N	  =	  234	   N	  =	  44	   0.18	  
	   0	  (-­‐8,	  8)	   0	  (-­‐10,	  8)	   	   0	  (-­‐4,	  5)	   -­‐0.5	  (-­‐7.5,	  4)	   	  
Highest	  Hb90	   N	  =	  435	   N	  =	  80	   0.83	   N	  =	  222	   N	  =	  42	   0.61	  
	   2.9	  (2.0,	  3.8)	   2.9	  (1.9,	  3.9)	   	   0.6	  (0.0,	  1.5)	   0.6	  (0.0,	  1.2)	   	  
Latest	  Hb90	   N	  =	  435	   N	  =	  80	   0.45	   N	  =	  222	   N	  =	  42	   0.23	  
	   2.2	  (1.3,	  3.0)	   2.2	  (0.7,	  3.2)	   	   0.1	  (-­‐0.4,	  1.2)	   0.0	  (-­‐0.4,	  0.8)	   	  
Highest	  PLT90	   N	  =	  223	   N	  =	  38	   0.78	   N	  =	  124	   N	  =	  26	   0.30	  
	   -­‐4	  (-­‐36,	  12)	   -­‐3	  (-­‐38,	  24)	   	   0	  (-­‐10,	  2)	   0	  (-­‐27,	  0)	   	  
Latest	  PLT90	   N	  =	  223	   N	  =	  38	   0.72	   N	  =	  124	   N	  =	  26	   0.31	  
	   -­‐4	  (-­‐39,	  12)	   -­‐3	  (-­‐42,	  24)	   	   0	  (-­‐10,	  2)	   0	  (-­‐27,	  0)	   	  
	  
Table 2D: Average value over most recent 90 days of post-randomization factors for cases and controls (1:5 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  
Average	  value	  over	  	  






N	  =	  101	  





N	  =	  52	  
P	  value	  
Average	  SBP90	   N	  =	  463	   N	  =	  86	   0.38	   N	  =	  234	   N	  =	  44	   0.78	  
	   133	  (123,	  146)	   136	  (127,	  146)	   	   137	  (127,	  148)	   137	  (124,	  150)	   	  
Average	  DBP90	   N	  =	  463	   N	  =	  86	   0.43	   N	  =	  234	   N	  =	  44	   0.97	  
	   73	  (67,	  80)	   75	  (67,	  81)	   	   72	  (66,	  80)	   74	  (64,	  79)	   	  
Average	  Hb90	   N	  =	  436	   N	  =	  80	   0.01	   N	  =	  222	   N	  =	  42	   0.49	  
	   12.6	  (11.9,	  13.1)	   12.2	  (11.3,	  12.9)	   	   10.4	  (9.6,	  11.2)	   10.3	  (9.8,	  10.9)	   	  
Average	  PLT90	   N	  =	  223	   N	  =	  39	   0.85	   N	  =	  124	   N	  =	  26	   0.69	  
	   231	  (183,	  279)	   230	  (172,	  301)	   	   228	  (192,	  282)	   225	  (182,	  291)	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Table 3A: Change from baseline value of post-randomization factors for cases and controls (1:10 matching) in 
each treatment arm.  
 
	   Darbepoetin	  alfa	   	   Placebo	   	  















N	  =	  52	  
P	  
value	  
Highest	  SBP	   N	  =	  1010	   N	  =	  101	   0.97	   N	  =	  520	   N	  =	  52	   0.07	  
	   20	  (8,33)	   18	  (5,40)	   	   14	  (0,30)	   21	  (5,31.5)	   	  
Highest	  DBP	   N	  =	  1010	   N	  =	  101	   0.90	   N	  =	  520	   N	  =	  52	   0.86	  
	   11	  (5,20)	   11	  (5,20)	   	   10	  (0,16)	   10	  (0,18)	   	  
Latest	  SBP	   N	  =	  1010	   N	  =	  101	   0.74	   N	  =	  520	   N	  =	  52	   0.51	  
	   -­‐2	  (-­‐14,10)	   0	  (-­‐16,13)	   	   0	  (-­‐12,10)	   -­‐1.5	  (-­‐15.5,10)	   	  
Latest	  DBP	   N	  =	  1010	   N	  =	  101	   0.95	   N	  =	  520	   N	  =	  52	   0.32	  
	   0	  (-­‐8,8)	   0	  (-­‐10,7)	   	   0	  (-­‐6,5)	   0	  (-­‐8,6)	   	  
Highest	  Hb	   N	  =	  1006	   N	  =	  100	   0.32	   N	  =	  518	   N	  =	  52	   0.94	  
	   3.7	  (2.8,4.5)	   4.0	  (2.8,4.8)	   	   1.2	  (0.3,2.1)	   1.2	  (0.4,1.9)	   	  
Latest	  Hb	   N	  =	  1006	   N	  =	  100	   0.38	   N	  =	  518	   N	  =	  52	   0.35	  
	   2.0	  (1.1,2.9)	   1.8	  (0.6,3)	   	   0	  (-­‐0.6,0.8)	   0	  (-­‐1.1,0.7)	   	  
Highest	  Dose	   N	  =	  1009	   N	  =	  100	   0.82	   N	  =	  518	   N	  =	  52	   0.73	  
	   130	  (40,400)	   160	  (35,310)	   	   0	  (0,30)	   0	  (0,30)	   	  
Latest	  Dose	   N	  =	  1009	   N	  =	  100	   0.67	   N	  =	  518	   N	  =	  52	   0.96	  
	   30	  (-­‐40,200)	   50	  (-­‐20,180)	   	   0	  (0,0)	   0	  (0,0)	   	  
Highest	  PLT	   N	  =	  1008	   N	  =	  98	   1.00	   N	  =	  517	   N	  =	  52	   0.37	  
	   5	  (0,36)	   6	  (0,36)	   	   0	  (0,29)	   0	  (0,17.5)	   	  
Latest	  PLT	   N	  =	  1008	   N	  =	  98	   0.61	   N	  =	  517	   N	  =	  52	   0.32	  
	   -­‐0.9	  (-­‐35,11)	   0	  (-­‐24,12.6)	   	   0	  (-­‐20.4,10)	   0	  (-­‐32,1.5)	   	  
 
Table 3B: Average value over entire follow-up of post-randomization factors for cases and controls (1:10 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  















N	  =	  52	  
P	  
value	  
Average	  SBP	   N	  =	  1010	   N	  =	  101	   0.79	   N	  =	  520	   N	  =	  52	   0.51	  
	   134.5	  (127.2,143.5)	   131.8	  (126.4,145.8)	   	   136.6	  (128.5,146.2)	   138	  (133.1,144.9)	   	  
Average	  DBP	   N	  =	  1010	   N	  =	  101	   0.46	   N	  =	  520	   N	  =	  52	   0.29	  
	   72.8	  (67.1,77.9)	   73.7	  (67.4,78.8)	   	   71.9	  (66.5,78.3)	   74.8	  (66.7,78.3)	   	  
Average	  Hb	   N	  =	  1009	   N	  =	  100	   <0.001	   N	  =	  518	   N	  =	  52	   0.03	  
	   12.3	  (11.7,12.6)	   12.1	  (11.3,12.5)	   	   10.4	  (9.8,11.1)	   10.2	  (9.6,10.7)	   	  
Average	  weekly	  dose	   N	  =	  1009	   N	  =	  100	   0.68	   N	  =	  518	   N	  =	  52	   0.18	  
	   51.1	  (7.2,136.3)	   53.8	  (7.8,124.7)	   	   0	  (0,1.7)	   0	  (0,4)	   	  
Average	  PLT	   N	  =	  1009	   N	  =	  99	   0.23	   N	  =	  518	   N	  =	  52	   0.68	  
	   228	  (187,271.1)	   244.7	  (196.6,295)	   	   238.4	  (198.2,279.5)	   245.2	  (200.2,277.8)	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Table 3C: Change from baseline value of post-randomization factors for cases and controls (1:10 matching) in 
each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  
Change	  from	  
baseline	  to	  














N	  =	  52	  
P	  
value	  
Highest	  SBP90	   N	  =	  923	   N	  =	  86	   0.34	   N	  =	  468	   N	  =	  44	   0.57	  
	   7	  (-­‐4,20)	   6.5	  (0,23)	   	   2	  (0,20)	   0	  (-­‐4.5,23)	   	  
Highest	  DBP90	   N	  =	  923	   N	  =	  86	   0.26	   N	  =	  468	   N	  =	  44	   0.57	  
	   5	  (0,10)	   6	  (0,14)	   	   2	  (0,10)	   0	  (0,11)	   	  
Latest	  SBP90	   N	  =	  923	   N	  =	  86	   0.61	   N	  =	  468	   N	  =	  44	   0.55	  
	   -­‐2	  (-­‐14,10)	   0	  (-­‐16,13)	   	   0	  (-­‐12,10)	   -­‐0.5	  (-­‐14.5,7.5)	   	  
Latest	  DBP90	   N	  =	  923	   N	  =	  86	   0.63	   N	  =	  468	   N	  =	  44	   0.27	  
	   0	  (-­‐8,8)	   0	  (-­‐10,8)	   	   0	  (-­‐5.5,5)	   -­‐0.5	  (-­‐7.5,4)	   	  
Highest	  Hb90	   N	  =	  864	   N	  =	  80	   0.89	   N	  =	  438	   N	  =	  42	   0.78	  
	   2.8	  (2,3.8)	   2.9	  (1.9,3.9)	   	   0.4	  (0,1.3)	   0.6	  (0,1.2)	   	  
Latest	  Hb90	   N	  =	  864	   N	  =	  80	   0.66	   N	  =	  438	   N	  =	  42	   0.75	  
	   2.2	  (1.2,3)	   2.2	  (0.7,3.2)	   	   0	  (-­‐0.5,0.8)	   0	  (-­‐0.4,0.8)	   	  
Highest	  PLT90	   N	  =	  470	   N	  =	  38	   0.99	   N	  =	  253	   N	  =	  26	   0.19	  
	   -­‐2.0	  (-­‐34,14)	   -­‐3.3	  (-­‐38,24)	   	   0	  (-­‐6,7)	   0	  (-­‐27,0)	   	  
Latest	  PLT90	   N	  =	  470	   N	  =	  38	   0.92	   N	  =	  253	   N	  =	  26	   0.20	  
	   -­‐3.2	  (-­‐35,14)	   -­‐3.3	  (-­‐41.9,24)	   	   0	  (-­‐7.9,7)	   0	  (-­‐27,0)	   	  
	  
Table 3D: Average value over most recent 90 days of post-randomization factors for cases and controls (1:10 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   	   Placebo	   	  
Average	  value	  
over	  	  















N	  =	  52	  
P	  
value	  
Average	  SBP90	   N	  =	  923	   N	  =	  86	   0.38	   N	  =	  468	   N	  =	  44	   0.78	  
	   133.7	  (124,145)	   135.6	  (126.5,145.7)	   	   136.7	  (126.7,147.4)	   137	  (124,149.8)	   	  
Average	  DBP90	   N	  =	  923	   N	  =	  86	   0.43	   N	  =	  468	   N	  =	  44	   0.97	  
	   72.8	  (66.2,78.7)	   74.6	  (66.5,80.5)	   	   71.9	  (65.3,80)	   73.7	  (64,79)	   	  
Average	  Hb90	   N	  =	  866	   N	  =	  80	   0.03	   N	  =	  438	   N	  =	  42	   0.45	  
	   12.5	  (11.8,13.1)	   12.2	  (11.2,12.9)	   	   10.4	  (9.7,11.2)	   10.3	  (9.8,10.9)	   	  
Average	  PLT90	   N	  =	  470	   N	  =	  39	   0.86	   N	  =	  253	   N	  =	  26	   0.50	  
	   225.1	  (185.2,282)	   230	  (172,301.4)	   	   236	  (194,281)	   225	  (181.9,291)	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Table 4A: Change from baseline value of post-randomization factors for cases and controls (1:15 matching) in 
each treatment arm.  
 





N	  =	  1395	  
Stroke	  
Cases	  
N	  =	  101	  
P	  value	   No	  Stroke	  
Controls	  
N	  =	  780	  
Stroke	  
Cases	  
N	  =	  52	  
P	  value	  
Highest	  SBP	   N	  =	  1395	   N	  =	  101	   0.81	   N	  =	  780	   N	  =	  52	   0.14	  
	   20	  (7,	  32)	   18	  (5,	  40)	   	   0	  (15,	  30)	   5	  (21,	  31.5)	   	  
Highest	  DBP	   N	  =	  1395	   N	  =	  101	   0.98	   N	  =	  780	   N	  =	  52	   0.86	  
	   10	  (5,	  20)	   11	  (5,	  20)	   	   0	  (9.5,	  16)	   0	  (10,	  18)	   	  
Latest	  SBP	   N	  =	  1395	   N	  =	  101	   0.85	   N	  =	  780	   N	  =	  52	   0.30	  
	   0	  (-­‐14,	  10)	   0	  (-­‐16,	  13)	   	   -­‐10	  (0,	  10)	   -­‐15.5	  (-­‐1.5,	  10)	   	  
Latest	  DBP	   N	  =	  1395	   N	  =	  101	   0.75	   N	  =	  780	   N	  =	  52	   0.45	  
	   0	  (-­‐8,	  8)	   0	  (-­‐10,	  7)	   	   -­‐6	  (0,	  5)	   -­‐8	  (0,	  6)	   	  
Highest	  Hb	   N	  =	  1390	   N	  =	  100	   0.10	   N	  =	  778	   N	  =	  52	   0.90	  
	   3.6	  (2.7,	  4.4)	   4.0	  (2.8,	  4.8)	   	   0.3	  (1.2,	  2.1)	   0.4	  (1.2,	  2.0)	   	  
Latest	  Hb	   N	  =	  1390	   N	  =	  100	   0.50	   N	  =	  778	   N	  =	  52	   0.29	  
	   2.0	  (1.0,	  2.9)	   1.9	  (0.6,	  3.0)	   	   -­‐0.5	  (0.0,	  0.8)	   -­‐1.1	  (0.0,	  0.7)	   	  
Highest	  Dose	   N	  =	  1394	   N	  =	  100	   0.75	   N	  =	  778	   N	  =	  52	   0.67	  
	   120	  (40,	  400)	   160	  (35,	  310)	   	   0	  (0,	  30)	   0	  (0,	  30)	   	  
Latest	  Dose	   N	  =	  1394	   N	  =	  100	   0.47	   N	  =	  778	   N	  =	  52	   0.95	  
	   30	  (-­‐40,	  200)	   50	  (-­‐20,	  180)	   	   0	  (0,	  0)	   0	  (0,	  0)	   	  
Highest	  PLT	   N	  =	  1392	   N	  =	  98	   0.68	   N	  =	  777	   N	  =	  52	   0.60	  
	   1	  (0,	  35)	   6	  (0,	  36)	   	   0	  (0,	  26)	   0	  (0,	  18)	   	  
Latest	  PLT	   N	  =	  1392	   N	  =	  98	   0.51	   N	  =	  777	   N	  =	  52	   0.35	  
	   -­‐2	  (-­‐37,	  9)	   0	  (-­‐24,	  13)	   	   -­‐21	  (0,	  7)	   -­‐32	  (0,	  2)	   	  
	  
Table 4B: Average value over entire follow-up of post-randomization factors for cases and controls (1:15 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   Placebo	  




N	  =	  1395	  
Stroke	  
Cases	  
N	  =	  101	  
P	  value	   No	  Stroke	  
Controls	  
N	  =	  780	  
Stroke	  
Cases	  
N	  =	  52	  
P	  value	  
Average	  SBP	   N	  =	  1395	   N	  =	  101	   0.94	   N	  =	  780	   N	  =	  52	   0.25	  
	   134.4	  (126.9,	  143.2)	   131.8	  (126.4,	  145.8)	   	   128.2	  (135.9,	  145.1)	   133.1	  (138.0,	  144.9)	   	  
Average	  DBP	   N	  =	  1395	   N	  =	  101	   0.33	   N	  =	  780	   N	  =	  52	   0.34	  
	   72.5	  (67.0,	  77.8)	   73.7	  (67.4,	  78.8)	   	   66.5	  (72.1,	  78.2)	   66.7	  (74.8,	  78.3)	   	  
Average	  Hb	   N	  =	  1394	   N	  =	  100	   <0.001	   N	  =	  778	   N	  =	  52	   0.02	  
	   12.3	  (11.8,	  12.7)	   12.1	  (11.3,	  12.5)	   	   9.8	  (10.5,	  11.1)	   9.6	  (10.2,	  10.7)	   	  
Average	  weekly	  dose	   N	  =	  1394	   N	  =	  100	   0.98	   N	  =	  778	   N	  =	  52	   0.19	  
	   49.0	  (4.9,	  143.2)	   53.8	  (7.8,	  124.7)	   	   0	  (0,	  1.6)	   0	  (0,	  4.0)	   	  
Average	  PLT	   N	  =	  1393	   N	  =	  99	   0.35	   N	  =	  777	   N	  =	  52	   0.55	  
	   231	  (188,	  275)	   245	  (197,	  295)	   	   199	  (239,	  280)	   200	  (245,	  278)	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Table 4C: Change from baseline value of post-randomization factors for cases and controls (1:15 matching) in 
each treatment arm.  
	   Darbepoetin	  alfa	   Placebo	  
Change	  from	  
baseline	  to	  




N	  =	  1395	  
Stroke	  
Cases	  
N	  =	  101	  
P	  value	   No	  Stroke	  
Controls	  
N	  =	  780	  
Stroke	  
Cases	  
N	  =	  52	  
P	  value	  
Highest	  SBP90	   N	  =	  1282	   N	  =	  86	   0.80	   N	  =	  699	   N	  =	  44	   0.44	  
	   7	  (-­‐3,	  20)	   6.5	  (0,	  23)	   	   132	  (143,	  160)	   131	  (140,	  159)	   	  
Highest	  DBP90	   N	  =	  1282	   N	  =	  86	   0.37	   N	  =	  699	   N	  =	  44	   0.77	  
	   5	  (0,	  12)	   6	  (0,	  14)	   	   70	  (78,	  84)	   70	  (78,	  84)	   	  
Latest	  SBP90	   N	  =	  1282	   N	  =	  86	   0.80	   N	  =	  699	   N	  =	  44	   0.35	  
	   0	  (-­‐14,	  10)	   0	  (-­‐16,	  13)	   	   125	  (137,	  150)	   122	  (135.5,	  148)	   	  
Latest	  DBP90	   N	  =	  1282	   N	  =	  86	   0.79	   N	  =	  699	   N	  =	  44	   0.42	  
	   0	  (-­‐8,	  8)	   0	  (-­‐10,	  8)	   	   64	  (70,	  80)	   62.5	  (70,	  80)	   	  
Highest	  Hb90	   N	  =	  1221	   N	  =	  80	   0.68	   N	  =	  661	   N	  =	  42	   0.89	  
	   2.8	  (1.9,	  3.7)	   2.9	  (1.9,	  3.9)	   	   0.0	  (0.5,	  1.3)	   0.0	  (0.6,	  1.2)	   	  
Latest	  Hb90	   N	  =	  1221	   N	  =	  80	   0.96	   N	  =	  661	   N	  =	  42	   0.57	  
	   2.0	  (1.1,	  2.9)	   2.2	  (0.7,	  3.2)	   	   -­‐0.4	  (0.0,	  0.9)	   -­‐0.4	  (0.0,	  0.8)	   	  
Highest	  PLT90	   N	  =	  687	   N	  =	  38	   0.71	   N	  =	  372	   N	  =	  26	   0.35	  
	   -­‐4	  (-­‐39,	  10)	   -­‐3	  (-­‐38,	  24)	   	   -­‐10	  (0,	  0)	   -­‐27	  (0,	  0)	   	  
Latest	  PLT90	   N	  =	  687	   N	  =	  38	   0.67	   N	  =	  372	   N	  =	  26	   0.40	  
	   -­‐5	  (-­‐40,	  10)	   -­‐3	  (-­‐42,	  24)	   	   -­‐11	  (0,	  0)	   -­‐27	  (0,	  0)	   	  
	  
Table 4D: Average value over most recent 90 days of post-randomization factors for cases and controls (1:15 
matching) in each treatment arm.  
	   Darbepoetin	  alfa	   Placebo	  
Average	  value	  
over	  	  




N	  =	  1395	  
Stroke	  
Cases	  





N	  =	  780	  
Stroke	  
Cases	  
N	  =	  52	  
P	  
value	  
Average	  SBP90	   N	  =	  1282	   N	  =	  86	   0.38	   N	  =	  699	   N	  =	  44	   0.95	  
	   134.0	  (124.0,	  145.0)	   135.6	  (126.5,	  145.7)	   	   126.7	  (136.7,	  147.0)	   124.0	  (137.0,	  149.8)	   	  
Average	  DBP90	   N	  =	  1282	   N	  =	  86	   0.19	   N	  =	  699	   N	  =	  44	   0.83	  
	   72.7	  (66.0,	  78.7)	   74.6	  (66.5,	  80.5)	   	   65.3	  (72.0,	  80.0)	   64.0	  (73.7,	  79.0)	   	  
Average	  Hb90	   N	  =	  1225	   N	  =	  80	   0.02	   N	  =	  661	   N	  =	  42	   0.24	  
	   12.5	  (11.8,	  13.1)	   12.2	  (11.3,	  12.9)	   	   9.7	  (10.5,	  11.2)	   9.8	  (10.3,	  10.9)	   	  
Average	  PLT90	   N	  =	  687	   N	  =	  39	   0.85	   N	  =	  372	   N	  =	  26	   0.52	  
	   226	  (185,	  273)	   230	  (172,	  301)	   	   192	  (238,	  282)	   182	  (225,	  291)	   	  
 
